Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-05-18 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
东莞证券关于特一药业使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring institution (东莞证券股份有限公司) regarding the use of idle raised funds by 特一药业集团股份有限公司 to temporarily supplement working capital. It references regulatory approvals, the amount and use of raised funds, board approvals, and compliance with stock exchange rules. The document is a formal verification or audit opinion on a specific financing use case rather than a full financial report, earnings release, or capital update. It does not contain comprehensive financial statements or quarterly/yearly results. It is not a report publication announcement since it contains substantive content and analysis. The document fits best as an Audit Report / Information (AR) because it is a standalone audit/verification report on the use of funds and compliance with regulations, issued by the sponsoring institution and referencing audit confirmations by an accounting firm. Q2 2021
2021-05-18 Chinese
关于拟投资设立全资子公司的公告
Board/Management Information Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the proposed investment to establish a wholly-owned subsidiary, 广东特美健康科技产业有限公司. It details the investment overview, business rationale, board meeting approvals, and risk disclosures. There are no financial statements or detailed financial performance data included. The document focuses on corporate governance and management decisions related to the establishment of a new subsidiary. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a regulatory certification or a voting result announcement. The content fits best under Board/Management Information (MANG) as it announces a significant management decision and board approval related to corporate structure and investment.
2021-05-18 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the temporary use of idle raised funds to supplement working capital. It details the approval by the board, the amount of funds involved, the regulatory approvals, and assurances that the use of funds does not change their intended purpose. The document references regulatory compliance and approvals but does not contain financial statements or detailed financial data. It is a formal disclosure about the use of funds raised through convertible bonds, not a financial report or earnings release. The document length is under 5,000 characters and is primarily an announcement of a corporate financing-related decision. Therefore, it fits best under Capital/Financing Update (CAP).
2021-05-18 Chinese
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the use of idle raised funds to temporarily supplement working capital. It references regulatory guidelines and internal company rules related to the use of raised funds. The document is short (753 characters) and consists mainly of an opinion statement rather than a full financial report or detailed audit. It does not contain financial statements or comprehensive financial data. This type of document is typically a regulatory or compliance filing related to corporate governance and fund usage, but not a full audit report or annual report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2021-05-18 Chinese
关于第四届监事会第十八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 18th meeting of the 4th Supervisory Board of 特一药业集团股份有限公司. It details decisions about investment in a wholly-owned subsidiary and the temporary use of idle raised funds to supplement working capital. The document is short (1023 characters) and is a formal announcement of meeting resolutions rather than a full report or financial statement. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. The content relates to supervisory board meeting decisions, which aligns with Board/Management Information filings. Therefore, the document is best classified as Board/Management Information (MANG).
2021-05-18 Chinese
关于提前归还暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of temporarily supplemented working capital from raised funds. It references previous board resolutions and public announcements about the use of idle raised funds for working capital. The document is short (781 characters) and primarily informs about a financial operation related to capital usage and repayment. It does not contain financial statements, detailed financial results, or comprehensive report data. It is an update on capital usage and repayment, which fits the category of Capital/Financing Update (CAP).
2021-05-13 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.